Project
Centre of Experimental Medicine SAS
International Projects
IMPROVE - 3Rs concepts to improve the quality of biomedical science (IMPROVE)
3Rs koncepty pre zlepšenie kvality biomedicínskych vied (IMPROVE)
| Duration: | 21. 10. 2022 - 20. 10. 2026 |
| Evidence number: | CA21139 |
| Program: | COST |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena ERT |
| Annotation: | Awareness of the existence of a reproducibility and predictability crisis in biomedical science has increased in recent years. The reproducibility crisis refers to the problem that researchers struggle to replicate or reproduce scientific studies. There has been many publications reviewing why preclinical research is irreproducible and lack of predictability, pointing this to deficiencies in reporting and statistical practices. Confounding factors, which are part of the laboratory environment and will influence both the dependent and independent variables, continue to be identified, suggesting that our knowledge of their existence is far from complete. Better statistical methodology will play a central role in improving the reproducibility of science to produce robust and reproducible research. Another area of improvement is the development of novel methods to better define and assess replication success and improve predictability. Under this light, the development and introduction of new, powerful concepts for biomedical research is essential to reduce the production of non-reproducible and non-predictive data. This has immense scientific, economic and social significance. In this context, we propose that the findings and concepts from the 3Rs field can greatly help to improve biomedical research on several levels. Therefore, the main aim of the COST Action IMPROVE is: To establish a network which will work to refine, harmonise and promote 3Rs concepts, data and documents, in order to improve the quality of biomedical science. |
| Project web page: | https://www.cost.eu/actions/CA21139/ |
-
Efekty inhibítorov sodíkovo-glukózového transportéru 2 a kvercetínu, prírodného antioxidantu na myokardiálne ischemicko-reperfúzne poškodenie po kardioplégii
| Duration: | 1. 7. 2024 - 30. 6. 2026 |
| Evidence number: | APVV-SK-AT-23-0024 |
| Program: | Bilaterálne - iné |
| Project leader: | Mgr. Ferenczyová Kristína PhD. |
EU-RESOLVE - Európska sieť pre biológiu rezolúcie zápalu (EU-RESOLVE)
EU-Resolution Biology Network (EU-RESOLVE)
| Duration: | 15. 10. 2026 - 14. 10. 2029 |
| Evidence number: | CA24138 |
| Program: | COST |
| Project leader: | doc. RNDr. Pecháňová Oľga DrSc. |
| Annotation: | EU-RESOLVE aims to create a multidisciplinary, pan-European network of excellence in Resolution Biology. This network will bring together academics, clinicians, biotechnology companies, and other stakeholders. EU-RESOLVE will advance the understanding of the mechanisms that regulate the resolution of inflammation and accelerate the translation of these findings into more effective treatments for patients with inflammatory diseases. |
| Project web page: | https://www.cost.eu/actions/CA24138/ |
NETSKINMODELS - Engineering novel 3D organotypic skin models
European Network for Skin Engineering and Modeling (NETSKINMODELS)
| Duration: | 15. 9. 2022 - 14. 9. 2026 |
| Evidence number: | CA21108 |
| Program: | COST |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena ERT |
| Annotation: | Over the past years, investigative and experimental dermatology has developed various approaches, ranging from utilisation of ex-vivo skin tissues to establishment of reconstructed in-vitro and in-silico skin models as tools in both basic and translational skin research. These models have the strong potential to increase the significance of scientific and clinical outcomes and to reduce animal experimentation. Nevertheless, current skin models lack sophistication and standardisation, thereby hampering their wider acceptance by the scientific community and regulatory bodies. This is partly caused by a lack of cross talk between relevant stakeholders — regulatory bodies, basic scientists, clinicians, and industry — whereby advances in new technologies have not delivered their full potential in this field. In the proposed Action, interdisciplinary and intersectoral research and coordinated initiatives will drive the development and validation of standout sophisticated cell-based and computational skin models, including the development of artificial intelligence models for dermatological research. Furthermore, the Action has ambitions to develop ethical and sustainable reagents required for the elaboration of organotypic skin models, based on a strong partnership between network academia and industries. Harmonisation of scientific and technological knowledge and an enduring bottom-up dynamic in the field will be ensured by dissemination of leading-edge know-how among research intensive and research moderate European territories. Moreover, next-generation scientists will be trained for the long-term propagation and continued development of skin models. Action outcomes will turbocharge the field of skin models to meet rising scientific, clinical, economic, environmental and regulatory expectations, making Europe the epicentre of research in this field. |
| Project web page: | https://www.cost.eu/actions/CA21108/ |
EURESTOP - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections
Európska sieť na diagnózu a liečbu bakteriálnych ochorení rezistentných voči antibiotikám
| Duration: | 6. 10. 2022 - 5. 10. 2026 |
| Evidence number: | CA21145 |
| Program: | COST |
| Project leader: | RNDr. Májeková Magdaléna PhD. |
| Annotation: | The emergence and spread of drug-resistant bacteria is an important health and socioeconomic threat with global dimensions, which is developing towards an emergency/pandemic crisis. No drugs are available to address the disease, and diagnostic tools are poorly effective. This negatively impacts the treatment and survival of critically ill patients. Current research in this field is highly fragmented and mostly monodisciplinary, thus limiting the development of innovative diagnostic and therapeutic solutions. This COST Action will bring together industrial and academic European scientists with different skills and expertise in a multidisciplinary and concerted initiative. The Action will combine scientific disciplines in understanding the genetic and molecular bases of bacterial drug resistance, developing innovative diagnostic tools, and delivering lead/pre-clinical candidates, antibody-based therapies, and clinical-ready repurposed drugs towards the personalized treatment of drug-resistant bacterial infections. The further challenge of the Action is to enhance networking among European scientists and to train a new generation of young scientists skilled in the multiple aspects related to bacterial drug resistance. |
| Project web page: | https://eurestop.eu/ |
METAHEART - EUropean network to tackle METAbolic alterations in HEART failure
Európska sieť na riešenie metabolických zmien pri zlyhaní srdca
| Duration: | 18. 10. 2023 - 17. 10. 2027 |
| Evidence number: | CA 22169 |
| Program: | COST |
| Project leader: | doc. RNDr. Barteková Monika DrSc. |
| Project web page: | https://www.cost.eu/actions/CA22169/ |
RESIST-D - Reward-stress interactions as neurobiological substrate for resilience and vulnerability in mental health and depression: A translational large-scale project
Interakcia medzi odmenou a stresom ako neurobiologický podklad odolnosti a rezistencie v duševnom zdraví a depresii: Rozsiahly translačný projekt
| Duration: | 1. 1. 2024 - 31. 12. 2026 |
| Evidence number: | NEURON_RV-114 |
| Program: | ERANET |
| Project leader: | MUDr. Riečanský Igor DrSc. |
ONTOX - ONTOX - Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment
ONTOX - Testovanie opakovanej toxicity chemických látok na základe ontológie a umelej inteligencie za účelom hodnotenia rizík metódami NGRA
| Duration: | 1. 5. 2021 - 30. 12. 2026 |
| Evidence number: | H2020 |
| Program: | Horizont 2020 |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena ERT |
| Annotation: | The vision of the ONTOX project is to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animals in line with the principles of 21st century toxicity testing and next-generation risk assessment. Specifically, ONTOX will deliver a generic strategy to create innovative new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon the combination with tailored exposure assessment, will enable human risk assessment. This strategy can be applied to any type of chemical and systemic repeated dose toxicity effect. However, for proof-of-concept purposes, focus will be put on 6 specific NAMs addressing adversities in the liver (steatosis and cholestasis), kidneys (tubular necrosis and crystallopathy) and developing brain (neural tube closure and cognitive function defects) induced by a variety of chemicals, including from the pharmaceutical, cosmetics, food and biocide sectors. The 6 NAMs will each consist of a computational system based on cutting-edge artificial intelligence (AI) and will be primarily fed by available biological/mechanistic, toxicological/ epidemiological, physico-chemical and kinetic data. Data will be consecutively integrated in physiological maps, quantitative adverse outcome pathway networks and ontology frameworks. Data gaps, as identified by AI, will be filled by targeted state-of-the-art in vitro and in silico testing. The 6 NAMs will be evaluated and applied in collaboration with industrial and regulatory stakeholders in order to maximise end-user acceptance and regulatory confidence. This is anticipated to expedite implementation in risk assessment practice and to facilitate commercialisation. ONTOX will have a deep and long-lasting impact at many levels, in particular by consolidating Europe's world-leading position regarding the development, exploitation, regulation and application of animal-free methods for human risk assessment of chemicals. |
| Project web page: | www.ontox-project.eu |
RESCUE - Bridging the gap between cardiac and vascular regeneration
Preklenutie medzery medzi srdcovou a cievnou regeneráciou
| Duration: | 1. 1. 2024 - 31. 12. 2026 |
| Program: | Horizont Európa |
| Project leader: | doc. RNDr. Barteková Monika DrSc. |
| Annotation: | Our project has the ambition to develop innovative therapies based on RNA to simultaneously induce the regeneration of the muscular and vascular components of the heart after cardiac damage. Toward this goal, we will explore two hypotheses. The first hypothesis is that the regeneration of the muscular component in sufficient to trigger re-vascularization. The second hypothesis is that the two processes, the regeneration of the cardiac muscle and its blood vessels, need to be stimulated in parallel to achieve functional regeneration of the heart. Whatever the mechanism, our project will develop novel RNA drugs, encapsulated into lipid nanoparticles, able to simultaneously trigger the regeneration of the cardiac muscle and its effective vascularisation. |
CARA - Natural compounds against rheumatoid arthritis and its comorbidities, focus on prevention of blood–brain barrier disfunction
Prírodné látky pre terapiu reumatoidnej artritídy a jej komorbidít so zameraním na disfunkciu hematoencefalickej bariery
| Duration: | 1. 1. 2025 - 31. 12. 2026 |
| Evidence number: | CNR-SAS-2024-11 |
| Program: | Bilaterálne - iné |
| Project leader: | PharmDr. Bauerová Katarína PhD., DrSc. |
| Annotation: | We will study the effect of selected natural compounds from different sources and different molecular structures on arthritic symptoms of RA and on extra-arthritic events, focusing on BBB dysfunction and neuroinflammation. Our attention will focus on compounds not yet considered as potential adjuvant agents for RA treatment and that, accordingly with detailed literature research, may potentially act against RA and/or neuroinflammation Within the context of this project the SAS team will carry out the in vivo studies by using adjuvant arthritis model necessary to verify the effectiveness of the natural compounds selected in vitro by CNR colleagues. The SAS team will also carry out the assessment of specific inflammatory markers in plasma and in joint and spleen tissue samples. The SAS team will provide brain samples for CNR team. Further also NMR measurements in vivo will be done together with behavioral testing. |
Exploration of toxicology properties of drug candidates with antimicrobial and antiviral properties.
Skúmanie toxikologických vlastností kandidátov liečiv s antimikrobiálnymi a antivírusovými vlastnosťami
| Duration: | 1. 9. 2024 - 31. 12. 2026 |
| Evidence number: | PSCI Grant - 01 2024 |
| Program: | Multilaterálne - iné |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena ERT |
| Annotation: | The project focuses on exploring the toxicological properties of compounds with potential applications in the treatment of COVID-19. In vitro models of lung, nasal, and alveolar tissues will be employed to assess the safety and efficacy of drug candidates. This approach supports the development of novel therapeutic options while adhering to the principles of alternative testing methods. |
Validation of a Vaginal Irritation Protocol for the In Vitro Assessment of Medical Devices
Validácia protokolu vaginálnej iritácie pre hodnotenie zdravotníckych pomôcok in vitro
| Duration: | 1. 12. 2024 - 31. 12. 2026 |
| Program: | Multilaterálne - iné |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena ERT |
| Annotation: | The project aims to validate a reconstructed human vaginal model for in vitro testing of personal care products intended for use in the vaginal area. The results will be submitted to the ISO committee for potential implementation into the ISO 10993-23 standard, advancing safety assessment methodologies and promoting alternative testing approaches. |
CARDIOMIR - Developing new miRNA therapeutics for cardioprotection
Vývoj nových miRNA terapeutík pre kardioprotekciu
| Duration: | 1. 7. 2025 - 30. 6. 2027 |
| Evidence number: | SK-HU-24-0026 |
| Program: | Bilaterálne - iné |
| Project leader: | doc. RNDr. Barteková Monika DrSc. |
| Annotation: | Myocardial infarction (MI) is a top cause of mortality and disability worldwide. Despite the golden standard for the treatment of MI by timely reperfusion by the means of primary percutaneous coronary intervention (pPCI) saves lot of lives post-MI, there is still no cardioprotective compound on the market that could effectively prevent the consequences of MI or improve the effectiveness of reperfusion. Thus searching for the novel cardioprotective compounds is very much needed. Micro RNAs (miRNAs) are small non-coding RNA molecules that play a significant role in gene transcription regulation and have been found to play a role in the MI. Some of miRNAs have been reported to be involved in the development of the heart injury in MI, others have been identified as "protectomiRs", i.e., miRNAs with cardioprotective potential in MI. Based on these findings there is an extensive research in the field of developing miRNA-based therapeutics for cardioprotection. In line with this trend, the current project is aimed to identify the most efficient miRNAs for cardioprotection against MI-induced heart injury and to optimize the mode of delivery of these protectomiRs to the heart by searching the optimal carriers or vehicles for their application. |
National Projects
Targeted suppression of pro-inflammatory and pro-fibrotic signalling pathways to prevent life-threatening heart failure and malignant arrhythmias
Cielená modulácia pro-zápalových a pro-fibrotických signálnych dráh ako protekcia pred srdcovým zlyhávaním a život ohrozujúcimi arytmiami.
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Program: | VEGA |
| Project leader: | RNDr. Szeiffová Bačová Barbara PhD. |
The Role of Thyroid Hormones and the NRF2–PPARα Signaling Axis in the Regulation of Lipid Metabolism in a Rat Model of Cardiometabolic Comorbidity
Úloha tyroidných hormónov a signalizačnej osi NRF2–PPARα v regulácii lipidového metabolizmu v modeli kardiometabolickej komorbidity u potkanov
| Duration: | 1. 1. 2026 - 31. 12. 2027 |
| Evidence number: | Open-Mob-2025-03 |
| Program: | Iné projekty |
| Project leader: | RNDr. Bernátová Iveta DrSc. |
| Annotation: | Western diet (WD) significantly contributes to the development of cardiometabolic disorders (CMDs), including (pre)hypertension, dyslipidaemia, and metabolic-associated fatty liver disease (MAFLD). Thyroid hormones are key regulators of lipid metabolism, influencing cholesterol synthesis, clearance, and lipolysis. Altered thyroid hormone homeostasis, possibly induced by WD-related metabolic stress, may contribute to dyslipidaemia and increased CMD risk. Thyroid dysfunction can impair PPARα signalling, reduce fatty acid oxidation, and promote hepatic lipid accumulation. In this bilateral project, we aim to elucidate the role of thyroid hormones in WD-induced metabolic dysregulation using borderline hypertensive rats (BHR). Rats will be fed WD with or without dimethyl fumarate (DMF), a known activator of NRF2, a transcription factor involved in mediating antioxidant defences to maintain redox homeostasis and suppress inflammation. We will analyse how WD modulates thyroid hormone status, the expression of genes encoding NRF2 (Nfe2l2), PPARα (Ppara), and other genes involved in lipid metabolism in blood, the liver and heart. Blood pressure and biochemical markers (plasma lipid profile, markers of liver and heart damage and thyroid hormones) will be assessed alongside gene expression profiles in thyroid gland, pituitary, and metabolic tissues. This project will help clarify the molecular link between thyroid hormone signalling, NRF2–PPARα pathways, and lipid homeostasis in a rat model of cardiometabolic comorbidity induced by chronic WD intake, which may be useful to understand the development of CMDs in humans. |
BIOCARD - -
Bioenergetická a proteomická diagnostika v kardioprotekcii: efektívny nástroj v sledovaní regulácie mitochondriálnych signalizačných dráh.
| Duration: | 1. 7. 2023 - 30. 6. 2027 |
| Evidence number: | APVV-22-0264 |
| Program: | APVV |
| Project leader: | Ing. Ferko Miroslav PhD. |
| Annotation: | Oxygen-limited supply significantly increases the myocardial energy requirements. The onset of compensatory mechanisms against this disorder is associated with regulation at the level of cardiac mitochondria. It is mitochondrial dysfunction that is currently the goal of a therapeutic cardioprotective strategy. This project will combine the latest scientific insights with state-of-the-art methodological approaches. A key aspect of the presented research is to ensure sufficient energy production in the heart in conditions of increased energy requirements caused by reduced oxygen utilization and ischemic heart disease in combination with various types of preconditioning. The use of modern methodology will allow for investigation into the complex structure of mitochondrial protein signaling pathways, their regulations, proteome and metabolome alterations in heart and mitochondria. Description and comprehension of complex system of protein interactions can help identify signaling pathways in cardioprotection processes. Changes at the level of mitochondrial respiratory chain complexes that play an important role in the cellular energy maintenance will also be identified. One of the considered mechanisms of cardioprotection is the inhibition of mitochondrial permeability transition pores (mPTP) opening. Regulation of mPTP in terms of changes of individual proteins has already been presented. We aim to contribute to the understanding of the protein interactions presumably related to the protective modulation of mPTP. In connection with the remodeling of mitochondrial function, calcium homeostasis and signaling of free oxygen radicals will also be monitored. The presented project will deal with the stimulation of adaptation processes in order to contribute to the elimination of mitochondrial dysfunction and ensure the maintenance of dynamic balance under conditions of energy deprivation in diseased heart. |
PAIS-LC - Biomarkers and pathomechanisms of endothelial cell and erythrocyte dysfunction in patients with long COVID and cardiovascular comorbidities
Biomarkery a patomechanizmy dysfunkcie endotelových buniek a erytrocytov u pacientov s dlhým COVID-om a kardiovaskulárnymi komorbiditami
| Duration: | 1. 9. 2025 - 31. 8. 2029 |
| Evidence number: | APVV-24-0225 |
| Program: | APVV |
| Project leader: | MUDr. RNDr. Púzserová Angelika PhD. |
| Annotation: | COVID-19 is a viral infectious disease caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many millions of SARS-CoV-2 infection survivors, including both adults and children, live with chronic, systemic, and often disabling conditions commonly known as long COVID (LC). LC denotes a collection of long-term health consequences caused by the infection. The impact of LC is not limited to the health and quality of life of individual patients. Owing to its prevalence and the breadth of its clinical manifestations, it represents a major public health crisis; it strains health systems and national economies and threatens progress in global health, including the Sustainable Development Goals. Extensive literature supports the association between infection and cardiovascular (CV) complications, as well as an increased CV risk following infection. Endothelial dysfunction (ED) is a central pathomechanism in acute COVID-19 and has also been identified as a key pathogenic mechanism in the pathogenesis of LC. A growing number of studies highlight the significance of erythrocyte (Ery) abnormalities, abnormal clotting processes, excessive inflammation, and oxidative stress (OS) in LC patients. Different biomarker profiles may be associated with the variations in the clinical presentation (LC symptoms) and may suggest distinct pathomechanisms that are dominant in different patient subgroups. Although significant progress has been made in recent years in characterizing LC, many questions remain unanswered. Therefore, further studies and data are needed to develop effective and personalized therapeutic and preventive strategies. It is expected that the implementation of this project will contribute to elucidating the complex interplay between endothelial cells and Ery, the underlying pathomechanisms of ED in LC, and various aspects of the relationship between endothelial integrity changes, inflammation, OS, and hypercoagulable states. |
| Project web page: | www.dlhycovid.sk |
Biotechnological production and functional characterization of AKR1A1 enzyme for therapeutic applications
Biotechnologická produkcia a funkčná charakterizácia enzýmu AKR1A1 pre terapeutické aplikácie
| Duration: | 1. 1. 2026 - 31. 12. 2029 |
| Evidence number: | VEGA 2/0137/26 |
| Program: | VEGA |
| Project leader: | Ing. Šoltésová Prnová Marta PhD. |
| Annotation: | The project is focused on the biotechnological production, purification and functional characterization of recombinant human AKR1A1 enzyme to identify its substrate specificity and potential for therapeutic use. Optimization of expression systems and purification protocols will ensure a stable and functionally active enzyme. Comparison with the rat enzyme will allow evaluation of functional differences. The project uses a combination of biochemical, molecular and computational methods including enzyme kinetics. The results will contribute to the understanding of the role of AKR1A1 in xenobiotic metabolism, redox balance and pathophysiology, opening the way to its use in medicine and biotechnology. |
SUFIBAR - Targeted suppression of pro-inflammatory and pro-fibrotic signaling pathways to prevent heart failure and occurrence of malignant arrhythmias
Cielená supresia pro-zápalových a pro-fibrotických signálnych dráh pre zabránenie život ohrozujúceho zlyhávania srdca a výskytu malígnych arytmií
| Duration: | 1. 7. 2022 - 30. 6. 2026 |
| Evidence number: | APVV-21-0410 |
| Program: | APVV |
| Project leader: | RNDr. Szeiffová Bačová Barbara PhD. |
| Annotation: | Heart failure is characterized by a progressive reduction in cardiac output and occurrence of malignant arrhythmias resulting in substantial morbidity and mortality worldwide. Cardiac fibrosis, the key factor contributing to these life-threatening events, is still unresolved problem in clinic. Detection and management of myocardial fibrosis suffer from a lack of precision, therefore, novel approaches are extremely needed. We hypothesize that the determination of myocardial fibrosis phenotypes in a disease-specific way may reveal more precisely molecular targets for efficient prevention and/or treatment. The idea of the project is to differentiate myocardial fibrosis phenotypes via assessment of circulating markers of oxidative stress, inflammation and pro-fibrotic components along with determining the activation of actual signaling pathways and extent of fibrosis. In the same time to explore efficacy of selected compounds, AT1 receptor blocker, ACE inhibitor, melatonin, triiodothyronine, metoprolol, omega-3 fatty acids and molecular hydrogen, to suppress pro-inflammatory and pro-fibrotic signaling pathways including purinergic signaling mediated by connexin-43 hemichannels and panexin-1 channels and to prevent or attenuate adverse structural and electrical remodeling. Novel findings may provide fundamental input to targeted therapy aimed to reduce myocardial fibrosis burden and challenge to realize well designed clinical trials. |
DiPrev - Dimethyl fumarate as a potential tool for the prevention of cardiovascular and hepatic disorders associated with Western diet in borderline hypertensive rats
Dimetylfumarát ako potenciálny nástroj na prevenciu kardiovaskulárnych a hepatálnych porúch spojených so západnou stravou u potkanov s hraničnou hypertenziou
| Duration: | 1. 9. 2024 - 31. 8. 2026 |
| Evidence number: | 09I03-03-V04-00427 |
| Program: | Plán obnovy EÚ |
| Project leader: | RNDr. Bernátová Iveta DrSc. |
ARISER - Consequences of combined therapy of maternal depression – experimental study in rat offspring
Dôsledky kombinovanej terapie materskej depresie – experimentálna štúdia u potomstva potkanov
| Duration: | 1. 9. 2025 - 30. 8. 2029 |
| Evidence number: | APVV-24-0391 |
| Program: | APVV |
| Project leader: | RNDr. Dubovický Michal CSc. |
| Annotation: | The lifetime risk of depression is higher in women than in men, and is particularly high during women's reproductive years. Untreated maternal depression not only threatens the health and life of the mother, but also increases the risk of impaired functional brain development in the fetus and newborn, which can lead to behavioral, psychosocial, and cognitive disorders later in life. Treatment of maternal depression includes psychotherapy and pharmacotherapy. While psychotherapy may be sufficient for mild to moderate depression, it often it often fails in moderate to severe depression. Antidepressants with well-studied reproductive safety profile, such as selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors are commonly considered as a first-line treatment. However, more than 5% of women with peripartum depression do not respond to standard drug treatment. In this case, it is necessary to use a different antidepressant, a combination of antidepressants, or add antipsychotic drugs. The necessity of pharmacotherapy in this case raises questions about the safety of using the combination of drugs and taking into account their possible risks for fetal and neonatal development, with an emphasis on functional brain development and neurobehavioral adaptations in the later period. According to available clinical knowledge, the combination of the selective serotonin reuptake inhibitor sertraline (SER) and the second-generation antipsychotic aripiprazole (ARI) represents the optimal choice for the treatment of maternal/psychotic depression. Our main objective is therefore to evaluate the safety of ARI and ARI+SER administration during pregnancy in an animal model of maternal depression with a focus on offspring development. To achieve this, we will study the effects of prenatal exposure to these drugs on functional brain development and neurobehavioral consequences in rat offspring. |
EXPERIMENTAL STUDY OF THE EFFECTS OF MATERNAL DEPRESSION AND ANTIDEPRESSANTS CITALOPRAM AND SERTRALINE ON POSTNATAL DEVELOPMENT OF RAT OFFSPRING
EXPERIMENTÁLNA ŠTÚDIA ÚČINKOV MATERSKEJ DEPRESIE A ANTIDEPRESIVNYCH LIEČIV CITALOPRAMU A SETRALINU NA POSTNATÁLNY VÝVIN POTOMSTVA POTKANOV
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 2/0133/23 |
| Program: | VEGA |
| Project leader: | RNDr. Dubovický Michal CSc. |
| Annotation: | Depressive disorders affect around 20% of women during pregnancy and breastfeeding. The most frequently prescribed antidepressants during pregnancy are selective serotonin reuptake inhibitors (SSRIs). However, the safety of their use in the treatment of maternal depression is controversial. The US Food and Drug Administration (FDA) classifies these antidepressants as Category C drugs, which means that there are currently no sufficient well-controlled studies to assess the risk of their administration to pregnant and breastfeeding women. In our experimental project, we will focus on researching citalopram and sertraline and their possible adverse (or therapeutic) effects on rat brain development when administered to pregnant rats alone or in combination with induced maternal depression. With this research, we want to contribute to a more comprehensive characterization of both drugs in terms of their safety in the treatment of maternal depression. |
Experimental real-life risk simulation approach: The effect of long-term exposure to a chemical mixture of pesticides, contaminants and food additives at low doses in extended one-generation reproductive toxicity study
Experimentálny prístup simulácie rizík v reálnom živote: Vplyv dlhodobej expozície chemickej zmesi pesticídov, kontaminantov a potravinových prísad v nízkych dávkach vo viacgeneračnej štúdii na potkanoch
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | 2/0163/24 |
| Program: | VEGA |
| Project leader: | RNDr. Mach Mojmír PhD. |
| Annotation: | In real life, mixtures of xenobiotics can lead to a 'cocktail' effect. Studies have shown that these mixtures can lead not only to predictable additive effects but also to unpredictable synergistic, or antagonistic effects. From early intrauterine life till elderly, the individual is continuously exposed to chemicals with beneficial or detrimental effects depending on the doses, windows of exposure and combinations. Many of these exposures are considered risk factors for many diseases. These observations indicate the necessity of using improved hazard-evaluation models, such as the real-life risk simulation (RLRS) scenario. The present project aims to to provide an evaluation of the pre- and postnatal effects of mixture of chemicals (below NOAEL levels) on development as well as a thorough evaluation of systemic toxicity in pregnant and lactating females and young and adult offspring. |
SERCA-AKTIV - Pharmacological Activation of SERCA: A Therapeutic Target for Chronic Metabolic Diseases
Farmakologická aktivácia SERCA púmp: terapeutický cieľ v manažmente chronických metabolických ochorení
| Duration: | 1. 9. 2025 - 31. 8. 2029 |
| Evidence number: | APVV-24-0186 |
| Program: | APVV |
| Project leader: | RNDr. Lomenová Jana PhD. |
| Annotation: | The proposed project focuses on the pharmacological activation of SERCA (Sarco/Endoplasmic Reticulum Ca²⁺-ATPase) as a therapeutic strategy to address chronic metabolic diseases, particularly type 2 diabetes mellitus. SERCA dysfunction, exacerbated by oxidative stress and post-translational modifications (PTMs), disrupts calcium homeostasis, increases ER stress, and contributes to beta-cell dysfunction and metabolic dysregulation. This multidisciplinary project aims to systematically evaluate SERCA activators and their role in modulating oxidative and ER stress under diabetic conditions. A set of 15–20 natural and synthetic compounds will be investigated for their effects on SERCA1a activity, oxidative modifications, conformational changes, and lipid peroxidation. In silico modeling will predict binding interactions and identify key allosteric sites, while ADME and toxicity evaluations will guide compound selection. The antioxidant capacity of these activators will be assessed, focusing on their ability to protect against MGX, PAL, and CYT-induced oxidative/ER stress and their correlation with SERCA function restoration. Ex vivo studies will evaluate RBC resistance to oxidative damage, while cellular studies will analyze viability, apoptosis, ROS levels, intracellular calcium levels, insulin secretion, SERCA2b expression, and mitochondrial function. Additionally, the ZDF rat model will serve as a comparative tool to examine tissue-specific changes in calcium-regulating proteins and oxidative stress and inflammatory markers in diabetes-related metabolic disturbances. This project aims to validate SERCA as a therapeutic target, investigate PTM involvement and compensatory mechanisms, and evaluate the role of antioxidant protection. The obtained findings will expand knowledge on calcium regulation and the therapeutic potential of SERCA in metabolic diseases. |
Targeting SERCA Activation: Therapeutic Strategies for Managing Endoplasmic Reticulum Stress in Chronic Metabolic Diseases
Farmakologická aktivácia SERCA púmp: význam v manažmente stresu endoplazmatického retikula pri chronických metabolických ochoreniach
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | 2/0127/25 |
| Program: | VEGA |
| Project leader: | RNDr. Lomenová Jana PhD. |
| Annotation: | Calcium homeostasis imbalance activates endoplasmic reticulum (ER) stress, leading to the development of chronic metabolic diseases. The dysfunction of Sarco/Endoplasmic Reticulum Ca2+-ATPases (SERCA) has been identified as a major causative factor of ER stress. Pharmacological activation of SERCA appears to be an effective strategy in alleviating ER stress. The project will investigate the activation of SERCA by polyphenolic compounds to mitigate damage to pancreatic cells induced by methylglyoxal, palmitate, and cytokines (experimental diabetic conditions). The efficacy of compounds will be evaluated based on the activation of isolated SERCA1a protein and at the cellular level, focusing on viability, apoptosis, SERCA2b expression, insulin release, intracellular calcium levels, reactive oxygen species formation, SIRT and PPAR activation, among others. The project will contribute to clarifying the mechanisms of hyperglycemia at the cellular level and the effect of new compounds capable of mitigating ER stress. |
| Project web page: | https://e-vega.sav.sk/(S(h22jztv2lbh35lvjyssbrer5))/users/Projekt_SAV_0007.aspx |
Targeting SERCA Activation: The impact of Novel Derivatives of Cemtirestat on Enhanced Pancreatic Beta-Cell Function in Diabetes Management
Farmakologická aktivácia SERCA: Vplyv nových derivátov cemtirestatu na zlepšenie funkcie pankreatických beta-buniek v liečbe cukrovky
| Duration: | 1. 1. 2026 - 31. 12. 2029 |
| Evidence number: | VEGA 2/0060/26 |
| Program: | VEGA |
| Project leader: | Ing. Micháliková Silvia PhD. |
| Annotation: | Preserving pancreatic beta-cell function is key in type 2 diabetes mellitus (T2DM) treatment, as endogenous substances contribute to beta-cell damage. This project investigates the effects of indole compounds (cemtirestat, an oxygenated CMTI derivative, and others) on SERCA modulation and beta-cell viability. Structural and functional changes in SERCA1a and INS-1E cells after methylglyoxal, palmitate, and cytokine damage will be assessed. Compound efficacy will be evaluated by SERCA1a activation and effects on cell viability, apoptosis, SERCA2b expression, insulin secretion, Ca2+ levels, ROS production, and SIRT/PPAR pathway activation. The goal is to deepen knowledge of hyperglycemia-related mechanisms and assess novel compounds' potential to reduce ER stress and glucotoxicity, including polypharmacological effects of aldose reductase inhibitors in diabetic complications. |
Targeting SERCA Activation: Therapeutic Strategies for Managing Endoplasmic Reticulum Stress in Diabetic Conditions
Farmakologická aktivácia SERCA: význam v manažmente stresu endoplazmatického retikula v diabetických podmienkach
| Duration: | 1. 1. 2025 - 31. 12. 2026 |
| Evidence number: | Open-Mob-2024-11 |
| Program: | Iné projekty |
| Project leader: | RNDr. Lomenová Jana PhD. |
| Annotation: | Calcium homeostasis imbalance activates endoplasmic reticulum (ER) stress, leading to the development of chronic metabolic diseases. The dysfunction of Sarco/Endoplasmic Reticulum Ca2+-ATPases (SERCA) has been identified as a major causative factor of ER stress. Pharmacological activation of SERCA appears to be an effective strategy in alleviating ER stress. The project will investigate the activation of SERCA by newly developed small allosteric SERCA activators to mitigate damage to pancreatic cells induced by methylglyoxal, palmitate, and/ or cytokines (experimental diabetic conditions). The efficacy of compounds will be evaluated based on the activation of isolated SERCA1a protein and at the cellular level, focusing on viability, apoptosis, insulin release, SERCA2b expression, intracellular calcium levels, reactive oxygen species formation, and metabolic analysis, among others. The project will contribute to clarifying the mechanisms of hyperglycemia at the cellular level and the effect of new compounds capable of mitigating ER stress. |
N/A - Pharmacological intervention in the treatment of cachexia by administering natural extracts (Crocus sativus and Ginkgo biloba) and substances (melittin, saffron, crocin, kaempferol and isorhamnetin) in combination with methotrexate and dexamethasone in an
Farmakologická intervencia v liečbe kachexie podávaním prírodných extraktov (Crocus sativus a Ginkgo biloba) a látok (melitín, šafranal, krocín, kempferol a izorhamnetín) v kombinácii s metotrexátom a dexametazónom na zvieracom modeli zápalovej kachexie.
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | VEGA 2/0126/23 |
| Program: | VEGA |
| Project leader: | PharmDr. Poništ Silvester PhD. |
| Annotation: | Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects the synovial joints and is also associated with extra-articular manifestations, including cachexia. Standard treatment of RA with methotrexate (MTX) and glucocorticoids (GC) may worsen cachexia. Thus, an important strategy of this project will be the suppression of cachexia using combination therapy, which will be based on the addition of natural anti-inflammatory substances to MTX and GC. In experimental arthritis, we will also investigate the effect of drugs and natural substances on markers of catabolism (myostatin and E3 ubiquitin-protein ligase) and anabolism (IGF-1, ghrelin, and testosterone) of skeletal muscle, on markers of systemic inflammation (IL-1beta, TNF-alpha, IL-6, MCP-1, IL-17A, MMP-9) and oxidative stress (4-hydroxynonenal, protein carbonyls, glutathione peroxidase, catalase) in plasma, which will help us to elucidate the mechanisms of inflammatory cachexia and it’s affecting by monotherapy and combination therapy. |
Pharmacological and nonpharmacological interventions to activate endogenous cardioprotection in failing heart.
Farmakologické a nefarmakologické intervencie na aktiváciu endogénnej kardioprotekcie v zlyhávajúcom srdci.
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | 2/0078/25 |
| Program: | VEGA |
| Project leader: | Mgr. Farkašová Veronika PhD |
| Annotation: | Heart failure (HF) is the final stage of several cardiovascular diseases, in particular, myocardial infarction (MI). Although the patients that successfully survive MI live longer, the alteration of the heart muscle will manifest later on by chronic failure of its pumping function. Potential reasons for that may be related to the complexity of the mechanisms of HF and the requirement for multitargeted effects of optimal cardioprotection. The project aims to study the possibility of reactivating adaptive potential in pathologically remodeled failing myocardium by pharmacological and nonpharmacological interventions. We will examine the effects of drugs with cardioprotective properties and intermittent hypoxia applied prior to administration of pathological stimulus and in various stages of the development of HF. We will focus on characterizing functional and structural changes in the myocardium and the specific signaling pathways associated with the origin and development of HF and cardioprotection. |
ITAGES - Identification of stress-induced alterations in expression of NRF2 target genes in rat models of prehypertension: the effect of comorbid hypertriglyceridemia and dimethyl fumarate treatment
Identifikácia stresom vyvolaných zmien v expresii cieľových génov NRF2 v potkaních modeloch prehypertenzie: vplyv komorbidnej hypertriglyceridémie a liečby dimetylfumarátom
| Duration: | 1. 7. 2023 - 30. 6. 2027 |
| Evidence number: | APVV-22-0296 |
| Program: | APVV |
| Project leader: | RNDr. Bernátová Iveta DrSc. |
| Annotation: | The nuclear transcription factor erythroid 2-related factor 2 (NRF2) is a key molecular link between several noncommunicable diseases, as it regulates the expression of approximately 250 target genes, including those involved in maintenance of redox balance, the development of metabolic disorders, cardiovascular and liver diseases, as well as in immune responses. Borderline elevated blood pressure (prehypertension) is a common cardiovascular disorder in humans, and elevated blood pressure has been found to be positively correlated with triglyceride levels. In addition, chronic stress is an etiological factor in the development of non-communicable diseases, including elevated blood pressure and hypertriglyceridemia (HTG). In experimental studies, borderline hypertensive rats (BHR) and hypertriglyceridemic rats (HTGR) are suitable models of prehypertension without and with comorbid hypertriglyceridemia. These models are relevant for investigating the effects of stress as well as for investigating the role of changes in expression of NRF2 target genes in the development of hypertension associated with metabolic diseases. To understand better the role of NFR2 as well as the impact of chronic social stress on thementioned diseased states, the aims of this project are: 1) to identify differences in expression of NRF2 target genes in two experimental models of prehypertension - without (in BHR) and with (in HTGR) comorbid HTG - in control conditions and during chronic social stress, 2) to determine if NRF2 activator dimethyl fumarate can reduce stress-induced pathologies in prehypertensive rats, especially in those with comorbid HTG, and 3) to specify a set of suitable whole blood RNA biomarkers for evaluation of changes in NRF2 target genes in prehypertension and HTG and those genes altered by chronic social stress. |
In vitro study of antioxidative/antiinflammatory effects of natural and synthetic compounds. In vivo assessment of medicinal effects of selected compounds in experiments of healing skin wounds.
In vitro štúdium antioxidačných/protizápalových účinkov prírodných a syntetických zlúčenín. In vivo dôkaz liečivých účinkov vybraných zlúčenín v experimentoch hojenia kožných rán.
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 2/0008/23 |
| Program: | VEGA |
| Project leader: | RNDr. Valachová Katarína PhD. |
-
Inhibícia ACE2 receptorov pri hypertenzii a obezite ako potenciálny model dôsledkov COVID-19: účinol S-nitrózokaptoprilu
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 2/0025/23 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga DrSc. |
Cardioprotective effects of mesenchymal stem cells and HMGB1 inhibitor after experimentally induced myocardial infarction
Kardioprotektívne účinky mezenchymálnych kmeňových buniek a inhibítora HMGB1 po experimentálne vyvolanom infarkte myokardu
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | 2/0131/24 |
| Program: | VEGA |
| Project leader: | RNDr. Cebová Martina PhD. |
| Annotation: | Myocardial infarction is a cardiovascular disease associated with remodeling as a result of ischemia. The absence of oxygen and nutrients during ischemia results in inflammation, oxidative damage, and tissue degeneration. For understanding of the onset and progression of myocardial protection mechanisms during ischemia, it is necessary to monitor signaling molecules that can block or reverse the pathological process. Despite advances in treatment, myocardial infarction still remains the leading cause of death in the world. The aim of the proposed project will be to clarify the initial molecular and morphological changes caused by both stem cell application and glycyrrhizin, an HMGB1 inhibitor, administrated after myocardial infarction with a focus on suppressing pro-inflammatory and pro-fibrotic pathways. The new results may provide information for targeted therapy aimed either at stem cells application or at the application of an HMGB1 inhibitor as an alternative for the myocardial infarction treatment. |
-
Kardioprotektívne účinky nových antidiabetík a antiobezitík u starších diabetických obéznych potkanov: komplexná analýza medzipohlavných rozdielov.
| Duration: | 1. 7. 2025 - 30. 6. 2029 |
| Evidence number: | APVV-24-0619 |
| Program: | APVV |
| Project leader: | Mgr. Ferenczyová Kristína PhD. |
SGLT2 Cardioprot - Cardioprotective effect of SGLT2 inhibition in heart failure: the role of RISK and SAFE pathway
Kardioprotektívne účinky SGLT2 inhibítora pri srdcovom zlyhávaní: úloha RISK a SAFE signálnej dráhy
| Duration: | 1. 9. 2024 - 31. 8. 2026 |
| Evidence number: | 09I03-03-V04-00389 |
| Program: | Plán obnovy EÚ |
| Project leader: | Mgr. Farkašová Veronika PhD |
| Annotation: | Heart failure (HF) is the final stage in several cardiovascular diseases (CVD) (cardiomyopathies, valvular or ischemic heart disease, acute myocardial infarction and many others). Myocardial infarction (MI) remains the most common cause of HF worldwide. For almost 50 years HF has been recognised as a determinant of adverse prognosis after MI. Although the patients that successfully survive MI live longer, the alteration of the heart muscle will manifest later on by chronic failure of its pumping function. Potential reasons of that may be related to the complexity of mechanisms of HF and the requirement for multitarget effects of optimal cardioprotection. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the newest class of antidiabetic drugs. Recently, clinical trials reported the cardiovascular benefits of empagliflozin, an SGLT-2 inhibitor, by significantly decreasing the incidence of hospitalization associated with HF and cardiovascular-cause death rate in diabetic patients with CVD and in HF patients. In addition, SGLT2 inhibitors (SGLT2i) exert cardioprotective effects in animal models of acute MI through a reduction of infarct size and a subsequent attenuation of HF development. Chronic treatment with Empagliflozin in mice with type 2 diabetes showed that the drug increased both the phosphorylation and the expression of cardiac signal transducer and activator of transcription 3 (STAT-3) at early reperfusion. STAT-3 is one of the main signaling molecules in the survivor-activating factor enhancement (SAFE) pathway. SAFE, together with the pro-survival reperfusion injury salvage kinase (RISK) pathway, are considered major mediators of cardioprotection against I/R injury, showing potential for SGLT2 inhibition as a cardioprotective drug candidate. The project aims to evaluate the effect of pharmacological conditioning with an SGLT2 inhibitor on cardiac resistance to acute myocardial infarction and subsequent HF and to determine the role of RISK and SAFE pathways in pharmacological conditioning with an SGLT2 inhibitor in hearts subjected to acute myocardial infarction and subsequent heart failure. |
CARDIOEND - Cardiovascular protection mediated by alpha 1 AMPK against metabolic syndrome-mediated endothelial dysfunction - identifying new risk factors
Kardiovaskulárna ochrana sprostredkovaná alfa 1 AMPK proti endotelovej dysfunkcii sprostredkovanej metabolickým syndrómom – identifikácia nových rizikových faktorov
| Duration: | 1. 7. 2023 - 30. 6. 2027 |
| Evidence number: | APVV-22-0154 |
| Program: | APVV |
| Project leader: | Ing. Tarcalová Miroslava PhD. |
| Annotation: | Disruption of vascular homeostasis caused by decreased nitric oxide bioavailability oxide due to oxidative stress and inflammation is the most serious complication of metabolic syndrome (MetS), leading to increased morbidity and mortality. There is an unmet need to identify key factors that prevent or protect vascular endothelium and thus improve primary and secondary prevention of cardiovascular diseases. It appears that AMP-dependent protein kinase (AMPK) may be such a factor. Its protective properties and positive effect on endothelial function and oxidative stress are already known. These unique properties suggest that AMPK may be involved in improving metabolic control during MetS, but still, the molecular changes due to α1AMPK-related dysregulation during MetS development are poorly understood. The project focuses on risk factors affecting endothelial function during MetS and the AMPK as a potential tool to modify those risk factors resulting in MetS prevention or treatment. The originality of the project is based on a comprehensive evaluation of functional, molecular, and biochemical changes in endothelial function, inflammation, and metabolic senescence during MetS with a detailed focus on vascular endothelium - proliferation, senescence, and apoptosis. The focus will be put on risk factors affecting endothelial function such as the interaction/adhesion of leukocytes with the vascular endothelium and the AMPK-dependent role of erythrocytes during MetS development. The project will be enriched by the study of phenotypic and molecular changes at the level of the CNS, with an emphasis on neuroinflammation and behavioral changes. Importantly, the project has a translation character, as human studies in patients with MetS will also be performed. The obtained results may represent a potential tool for improving the current population’s health and reducing the economic burden associated with the treatment of this cardiometabolic disease. |
Model of Western diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) in borderline hypertensive rats: effect of monomethyl fumarate
Model tukovej choroby pečene spojenej s metabolickou dysfunkciou (MAFLD) indukovanej príjmom diéty západného typu u hranične hypertenzných potkanov: vplyv monometylfumarátu
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | VEGA 2/0103/25 |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta DrSc. |
| Annotation: | Cardiovascular diseases (CMDs) and liver diseases are two of the leading causes of death worldwide. Primary prehypertension is a condition in which blood pressure is elevated above normal but not yet high enough to be classified as hypertension. It is a common condition, even in children and young adults. Individuals with prehypertension have an increased risk of developing CVDs and cardiometabolic diseases. To simulate the situation of women with prehypertension who consume a Western diet (WD), we will use an experimental model of female borderline hypertensive rats (BHR) fed a WD. We will investigate metabolic and functional changes, as well as changes in transcription of the nuclear factor erythroid 2-related factor 2 (NRF2) and its target genes, to better understand the mechanisms involved in the development of cardiovascular and hepatic disorders. The proposed model can provide a new tool for studying the interaction of mechanisms involved in the development of CVDs (such as hypertension) and cardiometabolic diseases (such as non-alcoholic fatty liver disease) in prehypertensive rats. The model can also be used to investigate whether dimethyl fumarate, an NRF activator, can be used for the prevention of these diseases. |
Modulating SERCA Pump Activity: Biochemical Studies in Isolated SERCA1a Enzyme and Pancreatic Beta-Cells.
Modulácia aktivity SERCA púmp: biochemické štúdie na izolovanom SERCA1a enzýme a pankreatických ß-bunkách.
| Duration: | 1. 1. 2026 - 31. 12. 2029 |
| Evidence number: | 2/0097/26 |
| Program: | VEGA |
| Project leader: | Mgr. Rezbáriková Petronela PhD. |
| Annotation: | Disruption of calcium homeostasis is a key trigger of endoplasmic reticulum (ER) stress, which contributes to the development of metabolic disorders such as type 2 diabetes mellitus. Dysfunction of calcium ATPases from the sarco/endoplasmic reticulum (SERCA) plays a central role in this process. The project focuses on evaluating the effects of selected compounds on SERCA activation and the protection of pancreatic ß-cells exposed to diabetogenic stressors (methylglyoxal, palmitate, cytokines). The research combines biochemical analysis of the isolated SERCA1a protein with functional studies in cell models. Emphasis is placed on enzyme activity, cell viability, apoptosis, insulin secretion, SERCA2b expression, and oxidative stress. The project is conducted in collaboration with the University of Michigan (USA), providing access to unique compounds and expertise in SERCA molecular pharmacology. The results will contribute to the development of new therapeutic strategies. |
-
Molekulárne a mechanobiologické mechanizmy konkurenčných a adaptačných stratégií nádorových buniek v odpovedi na nádorové mikroprostredie
| Duration: | 1. 7. 2025 - 30. 6. 2029 |
| Evidence number: | APVV-24-0090 |
| Program: | APVV |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena ERT |
| Annotation: | Cancer progression has been traditionally investigated in terms of genetic mutations. Recently, concept of heterogeneous “cancer cell states” in genetically identical cells has gained attention. Diverse cancer cells states emerge from adaptations to tumor microenvironment (TME), and can be transient and reversible. Understanding this complex phenomenon requires deep knowledge of underlying molecular and cellular mechanisms and their interrelationships. Diversity of cancer cell states is shaped by the TME spatial heterogeneity caused by hypoxia, shortage of nutrients and extracellular matrix (ECM) stiffness. Various strategies enable cancer cells in distinct TME niches to compete for space and resources. In addition to cell-autonomous processes, a currently elucidated mechanism of competition between adjacent cancer cells involves formation of cell-in-cell structures (CIC) for gain of nutrients in periods of starvation and/or protection from hostile environment. This mechanism requires activation of molecular pathways and mechanical adjustment to TME in order to promote survival and tumor microevolution. The main objective of this project is to bring original knowledge on how non-cellular components of TME affect competition and adaptation strategies of cancer cells and how they contribute to disease progression. Our focus will be on hypoxia and ECM stiffness, and particularly on the role of carbonic anhydrase IX (CA IX) as a molecule implicated in molecular and mechanobiological cancer cells’ responses to TME. We aim to exploit CA IX as a “molecular lens” enabling us (1) to uncover so far unknown mechanistic aspects of cell-in-cell structures as a strategy of cancer cell competition, and (2) to explore complex relationships among cancer cell subpopulations in diverse tumor tissue niches in response to TME heterogeneity. Results of this project are expected to advance understanding of tumor microevolution and reinforce rationale for clinical use of CA IX. |
CardCa2+CNS - Molecular mechanisms implicated in corticosteroid-monoamine interaction in stress-related cardio- and neuropathologies
Molekulárne mechanizmy interakcie signálnych dráh kortikosteroidov a monoamínov v kardio- a neuropatológiách vyvolaných stresom
| Duration: | 1. 7. 2023 - 30. 6. 2027 |
| Evidence number: | APVV-22-0061 |
| Program: | APVV |
| Project leader: | RNDr. Mach Mojmír PhD. |
| Annotation: | Stress is defined as an organism’s response to various stressors jeopardizing the homeostasis. Stressors accompany living organisms all through their life, when the first exposure happens even before the birth (e.g., maternal infection during the gestation). Stress is not necessarily harmful; controlled exposure to the certain stressors might be even beneficial (e.g., cognitive behavioral therapy). On the other side, stress can also be involved in certain heart and brain disorders, which are the worldwide leading causes for disability and mortality. Based on our previous results in rats, we hypothesize that interaction between corticosteroids and monoamines is a factor determining whether certain stressor, administered to the organism of the specific sex, will be harmful, neutral, or even beneficial. We aim to perform a further investigation of corticosteroid-monoamine interaction in rat model of prenatal stress (maternal infection during the gestation caused by LPS administration) and to assess a role of Ca2+ signaling, which decodes diverse extracellular signals into specific cellular responses. Particularly, we will focus on investigation of changes caused by prenatal stress at the level of cardiomyocyte contractility and excitability of serotonin and dopamine neurons in the midbrain. Ca2+ signaling as a potential intracellular effector of corticosteroid-monoamine interaction will be monitored at the level of intracellular Ca2+ channels, which are considered as the main components of Ca2+ signaling in cardiomyocytes as well in neurons. We will also test pyridoindoles as the novel treatment strategies for the stress-related cardiovascular and neurological disorders. This will include in silico modeling (computer simulations of drug interactions) and in vivo treatment. |
On the trace of mitochondrial chloride channel identity.
Na stope identity mitochondriálneho chloridového kanálu.
| Duration: | 1. 7. 2023 - 30. 6. 2027 |
| Evidence number: | APVV-22-0085 |
| Program: | APVV |
| Project leader: | Ing. Ferko Miroslav PhD. |
| Annotation: | Mitochondrial chloride channels are involved in the regulation of the mitochondrial membrane potential deltaΨm. In in vitro conditions, it was observed that oxidative stress results in oscillations of deltaΨm, which leads to the shortening of the action potential on the plasma membrane of cardiomyocytes and to the occurrence of arrhythmias, mediated by the production of ATP in the mitochondria. At the level of the whole heart, arrhythmias were observed as a consequence of ischemia-reperfusion. Specific ligands of the translocator protein (TSPO) prevent the occurrence of post-ischemic arrhythmias. The use of a non-specific chloride channel blocker led to the same effect. TSPO ligands inhibit the mitochondrial chloride channels at nanomolar concentrations, suggesting that the TSPO protein mediates the chloride channel block. Thus, TSPO is likely to be in close contact with the chloride channel. Mitochondrial chloride channels are well described at the electrophysiological level, but their molecular identity remains unclear. Recently, two isoforms of chloride intracellular channel family (CLICs) have been shown to be localized in mitochondria. However, CLIC channels have only been described in an artificial system - overexpressed in host cells. Mitochondrial chloride channels from native membranes are assumed to be identical to one of the two mitochondrial CLIC isoforms. The aim of the presented project is to verify the hypothesis that the measured native chloride channels from cardiac mitochondria are members of the CLIC family and whether the given CLIC isoform and TSPO are in close physical contact. We assume that the obtained results will help to clarify the molecular identity of the mitochondrial chloride channel, which represents a significant potential target for preventing the occurrence of post-ischemic arrhythmias. |
Neurocognitive mechanisms of semantic representation and control
Neurokognitívne mechanizmy sémantickej reprezentácie a kontroly
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 2/0052/23 |
| Program: | VEGA |
| Project leader: | Mgr. Marko Martin PhD. |
| Annotation: | Semantic cognition underpins the processing, organization, and fluid retrieval of knowledge (facts, concepts, and their relations) stored in memory. It regulates mental processes and adaptive behavior, whereas deterioration of this system is present among several neuropsychiatric disorders and diseases. The aim of this project is to identify cognitive and neurobiological mechanisms that support the ability to search and retrieve conceptual representations within semantic memory. For this purpose, we will carry out a set of original experiments that combine systematic manipulation of cognitive interference, the measurement of cognitive load (effort) using pupillometry, and non-invasive (transcranial) electrical brain stimulation. Via such interdisciplinary approach, we intent to characterize key neurocognitive determinants of automatic and control (executive) functions of the human semantic system, which may inspire effective interventions for their enhancement. |
Neuroprotective and cardioprotective potential of phenol acids in the prevention of civilization diseases
Neuroprotektívny a kardioprotektívny potenciál fenolových kyselín v prevencii civilizačných ochorení
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | VEGA 2/0018/23 |
| Program: | VEGA |
| Project leader: | RNDr. Gáspárová Zdenka PhD. |
| Annotation: | The risk of the civilization disease can be reduced by adjusting the lifestyle and a diet low in fat and increasing the intake of vegetables and fruits rich in flavonoids. These include phenolic acids (PA), small molecules with good bioavailability, and beneficial effects on the body. The project is focused on the cardioprotective and neuroprotective effects of PA on the heart and hippocampus of rats in vitro. After selecting the most effective PA from in vitro experiments, this will be tested in vivo in a model of a metabolic syndrome induced by a high fat-fructose diet. A project innovation lies in (i) the use of promising low molecular weight PA, and (ii) the application of magnetic resonance spectroscopy for non-invasive monitoring of the neurochemical profile changes in the rat brain. The determination of inflammation and oxidative stress markers offers to characterize the mechanism of action of the selected PA. The behavioral test (NOR) will provide data on learning and memory improvements. |
Neuroprotective potential of quercetin in aging diabetic ZDF rats
Neuroprotektívny potenciál quercetínu u starnúcich diabetických ZDF potkanov.
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | 2/0147/25 |
| Program: | VEGA |
| Project leader: | RNDr. Vlkovičová Jana PhD. |
Novel antidiabetic/antiobesty drugs as innovative pharmacotherapeutic tools for cardioprotection in experimental model of type 2 diabetes
Nové antidiabetiká/antiobezitiká ako inovatívny farmakoterapeutický nástroj kardioprotekcie v experimentálnom modeli diabetu 2. typu
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | VEGA 2/0159/24 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Barteková Monika DrSc. |
| Annotation: | Ischemic heart disease and myocardial infarction represent major diseases associated with myocardial ischemia-reperfusion (I/R) injury. Although several effective pharmacological and non-pharmacological protective interventions against myocardial I/R have been identified, translation of knowledge into clinical practice is uncertain, also due to comorbidities suffered by cardiac I/R patients, including diabetes and obesity. On the other hand, recently described cardioprotective effects of known antidiabetic drugs give hope for a comprehensive solution for therapy of cardiovascular and metabolic diseases in one. The aim of the project will be to investigate the possibilities of cardioprotection against I/R injury using new drugs with antidiabetic and antiobesity effects in an experimental model of type 2 diabetes. Results of the project will contribute to expanding the possibilities of therapy for cardiometabolic diseases, and thus to better management of patients suffering from civilization diseases |
CARDIOPROT - New aspects of cardioprotection by natural antioxidants: role of ageing and lifestyle-related comorbidities
Nové aspekty kardioprotekcie prírodnými antioxidantami: vplyv starnutia a komorbidít súvisiacich so životným štýlom
| Duration: | 1. 7. 2022 - 30. 6. 2026 |
| Evidence number: | APVV-21-0194 |
| Program: | APVV |
| Project leader: | doc. RNDr. Barteková Monika DrSc. |
| Annotation: | Despite the important progress in the treatment of cardiovascular disease (CVD), the new therapeutic strategies as well as mechanisms involved are still being extensively studied to reach the optimal efficiency of the therapy. Ischemia/reperfusion (I/R) injury represents a clinically relevant problem associated with CVD (including ischemic heart disease and myocardial infarction) as well as with cardiac surgery. Natural antioxidants including flavonoid quercetin and several catechins have been shown to exert protective effects against cardiac I/R injury. However, most of the experimental studies have been performed in young healthy animals what is not corresponding to the situation in real life where the patients prone to acute ischemic event (myocardial infarction) are usually aged people suffering from some comorbidities such as hypertension or metabolic disorders. Thus the aim of the current project is to reveal the real therapeutic potential of selected natural antioxidants, quercetin and epicatechin against cardiac I/R injury in aged subjects and subjects suffering from selected metabolic comorbidities (type 2 diabetes, hypertriglyceridemia) and hypertension. Another goal of the project is to uncover intra- as well as intercellular mechanisms involved in the action of selected antioxidantss in individuals with comorbidities exposed to cardiac I/R, including their interactions with mechanisms involved in development of selected comorbidities. Meeting the objectives of the project will significantly help to better management of patients suffering from CVD, particularly from acute myocardial infarction |
-
Nové možnosti prevencie oxidačného stresu pri dlhotrvajúcich operáciach s mimotelovým obehom
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | 2/0051/25 |
| Program: | VEGA |
| Project leader: | D.h.c., Prof., MUDr. Slezák Ján DrSc., FIACS |
QueProbio - New approach in post-traumatic stress disorder (PTSD) therapy: quetiapine treatment supplemented by probiotics
Nový prístup v terapii post-traumatickej stresovej poruchy (PTSD): liečba kvetiapínom doplnená o probiotiká
| Duration: | 1. 9. 2025 - 31. 8. 2029 |
| Evidence number: | APVV-24-0213 |
| Program: | APVV |
| Project leader: | RNDr. Mach Mojmír PhD. |
| Annotation: | Post-traumatic stress disorder (PTSD) is a multifaceted psychological disorder characterized by dysregulated fear and stress response. Its development affects variety of biological mechanisms including alterations in neurogenesis and brain neuroplasticity. Treatment of PTSD predominantly involves psychological interventions and pharmacotherapy comes out as a second option. Atypical antipsychotic quetiapine (QUE) is one of most promising agents used but besides suppressing the negative manifestations of PTSD it exerts also negative side effects. Recently, several studies have been focused on the involvement of intestinal microflora in psychiatric disorders and alterations in gut microbiome have also been connected with PTSD. However, the interconnections between antipsychotic treatment, gut microbiota and brain in PTSD have not been clarified yet. We assume that treatment with atypical antipsychotic QUE combined with probiotics may overcome disbiosis as an unwanted side effects of QUE and also improve the microbiota disbalance induced by PTSD. Combined treatment as suggested in the proposed project will represent a new trend in PTSD therapy. We believe that the proposed treatment may augment QUE therapeutic effect and suppress the negative behavioral manifestations and changes in the neuroplasticity induced by PTSD more effectively than single QUE therapy. This project will contribute to the better understanding of the mechanisms laying behind the development of PTSD pathology and may show a new perspective way of the PTSD treatment. |
-
Prepojenie medzi redoxnou signalizáciou, autofágiou a apoptózou pri rôznych typoch poškodenia srdcových buniek
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | VEGA 2/0091/25 |
| Program: | VEGA |
| Project leader: | Mgr. Svetláková (Boťanská) Barbora PhD. |
2/0091/23 - The contribution of new nano-carrier drug delivery systems to the enhancement of the anti-inflammatory effect of D-limonene, phellandrene, isoborneol and chrysophanol studied in vivo (2/0091/23)
Prínos nových nanonosičových liekových systémov k zvýšeniu protizápalového účinku D-limonénu, felandrénu, izoborneolu a chryzofanolu skúmaný in vivo (2/0091/23)
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 2/0091/23 |
| Program: | VEGA |
| Project leader: | PharmDr. Dráfi František PhD., MPH |
| Annotation: | Based on the scientific literature we hypothesize that an optimal anti-inflammatory effect of a selected natural substance after its oral administration in its new nano-carrier drug delivery systems (NCDDS) might beneficially modulate immune processes in inflammatory diseases as in rheumatoid arthritis (RA). Adjuvant arthritis (AA) is used as one of the in vivo RA models to evaluate the pharmacology of molecules tested. High bioavailability will be achieved by the technological adjustment of the molecules into NCDDS (nanoemulsions and liposomes). Along with other parameters evaluated and focused mainly on inflammation, we will analyze the ability to reduce bone erosion and/or synovitis by the RANKL/RANK/osteoprotegerin signalling pathway. The significant benefit will be statistically assessed by their dose-dependency evaluation and possible synergic/additive pharmacological determination of concomitantly applied standards as methotrexate and upadacitinib, administered both in (sub)therapeutic doses. |
PQC inhalation m - Preparation and quality control of modern dosage forms for alternative administration rout of biologics by inhalation (APVV-23-0508)
Príprava a kontrola kvality moderných liekových foriem pre alternatívne podanie biologík inhalačnou cestou (APVV-23-0508).
| Duration: | 1. 7. 2024 - 30. 6. 2028 |
| Evidence number: | APVV-23-0508 |
| Program: | APVV |
| Project leader: | PharmDr. Dráfi František PhD., MPH |
| Annotation: | The use of biopharmaceuticals has drastically expanded with the development of recombinant DNA technology. The typical delivery rout of the innovative drugs is based on intra venous, sub cutaneous, or intra muscular application. Pulmonary drug delivery offers rapid and sustained drug delivery, high efficacy, no first-pass metabolism, and achievement of both local and systemic effects. Development of such biologic demands making particles/droplets that are sufficiently small, and nebulization of the solution to be inhaled. Both aspects affect product quality through decreased activity or protein aggregation. It is essential to optimize the drug formulation with the intended delivery system used. The aim of the project is development of reliable and functional formulations of mAbs and peptides for their inhalation application. We expect that our project will bring comprehensive standard operation protocols or guidelines for formulation of such biologics. |
-
Protekcia kardiovaskulárneho systému pri experimentálnej hypertenzii a zlyhaní srdca inhibítorom sodíkovo-glukózového kontransportéra 2 -dapagliflozínom: efekt na srdce, cievy a obličky. Porovnanie s ACE inhibítorom kaptoprilom.
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 1/0048/23 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga DrSc. |
MITPROT - Heart mitochondria proteomic mapping: Uncovering potential signaling pathways
Proteomické mapovanie mitochondrií srdca: Odhaľovanie potenciálnych signálnych dráh
| Duration: | 1. 9. 2024 - 31. 8. 2026 |
| Evidence number: | 09I03-03-V04-00437 |
| Program: | Plán obnovy EÚ |
| Project leader: | Mgr. Andelová Natália PhD. |
| Annotation: | Exposure of the organism to limited access to oxygen is a significant stimulus in inducing cardioprotection effective against mitochondrial dysfunction. From the point of view of possible initiators of endogenous myocardium protection, hypoxia appears as a potential trigger of adaptation processes. Hypoxia-induced stimulation of the adaptive response induced by preconditioning represents an effective tool for maintaining the bioenergetic balance of the myocardium exposed to ischemia/reperfusion injury. Due to the dynamic nature of mitochondria, research attention is increasingly focused on their proteomic changes. Proteins are proving to be promising prognostic and diagnostic biomarkers. Modern analytical methods, such as mass spectrometry, which allows complex mapping of proteins and their changes, have a promising potential. Applying biostatistical approaches offers new concepts for studying protein-protein interactions (PPI) and characterizing signaling pathways involved in mitochondrial cardioprotective processes. Identifying mitochondrial proteome changes, elucidating calcium and reactive oxygen species signaling, regulating mitochondrial permeability transition pore opening, and studying PPI could provide a breakthrough understanding of signaling pathways from mitochondria to overall myocardial physiology. |
Rational design, synthesis and biological evaluation of novel aldose reductase inhibitors with improved antioxidant properties and bioavailability
Racionálny dizajn, syntéza a testovanie nových inhibítorov aldóza reduktázy s vylepšenými antioxidačnými vlastnosťami a biodostupnosťou
| Duration: | 1. 1. 2026 - 31. 12. 2029 |
| Evidence number: | VEGA 2/0124/26 |
| Program: | VEGA |
| Project leader: | RNDr. Kováčiková Lucia PhD. |
| Annotation: | To date, no specific class of therapeutics aimed at preventing or suppressing severe diabetes-associated complications has been available in Europe or the United States. Chronic exposure to elevated blood glucose levels adversely affects systemic homeostasis and may lead to cardiovascular toxicity, renal failure, cataract formation, and persistent inflammatory states with links to autoimmune and oncological disorders. Building on the prior identification of cemtirestat and its oxygen-containing analogue otirestat as starting structural scaffolds, and guided by rational design and structural optimization, we propose and investigate novel high-potency inhibitors with pronounced selectivity, antioxidant activity, and suitable bioavailability. Our primary scientific objective is the development of a drug candidate based on aldose reductase inhibition that would be attractive for pharmaceutical translation and further development toward a new therapeutic option for patients with diabetes and, potentially, other disorders associated with chronic inflammation. |
Semantic memory in mental health disorders
Sémantická pamäť pri poruchách mentálneho zdravia
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | VEGA 2/0067/25 |
| Program: | VEGA |
| Project leader: | MUDr. Riečanský Igor DrSc. |
Senogenic effects of environmental stressors in human skin cells and possibilities of senotherapy using natural and synthetic substances
Senogénne účinky environmentálnych stresorov v ľudských bunkách kože a možnosti senoterapie s využitím prírodných a syntetických látok.
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | VEGA 2/0060/24 |
| Program: | VEGA |
| Project leader: | Ing. Račková Lucia PhD. |
| Annotation: | Current knowledge indicates that organism-environment interaction affects rate of aging of the organism. Oxidative stress and inflammation are among the main gerontogenic mechanisms triggered by environmental stressors. These mechanisms are also linked to cellular senescence, process believed to contribute critically to aging.The skin, which is barrier organ of body, is constitutively exposed to various stimuli affecting its morphology and function.Therefore, skin exposome research can be considered paradigmatic,and its implementation can contribute to better understanding of aging in other organs as well. The aim of project is investigation of senogenic effects of various environmental stressors (such as oxidants,pollutants,UV radiation) also using new aging biomarkers. The scope of research also includes therapeutic efficacy of selected plant metabolites and synthetic compounds.The project will provide insight into gerontogenic and senotherapeutic mechanisms of substances studied in cellular skin models. |
Sensory control of postural balance and its changes due to motor, cognitive and anxiety disorders
Senzorická regulácia rovnováhy a jej zmeny vplyvom motorických, kognitívnych a úzkostných porúch
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | 2/0098/25 |
| Program: | VEGA |
| Project leader: | RNDr. Kimijanová Jana PhD. |
| Annotation: | In everyday life, we are constantly confronted with numerous situations in which individual sensory systems provide conflicting or ambiguous information and with new postural tasks to which we must adapt. Sensory integration plays a key role and the research of its mechanisms is very important for the assessment of balance control, especially in populations that are more prone to the risk of falling, i.e., in the elderly and patients with motor, cognitive or anxiety deficits. Appropriate motor or sensory intervention can help these vulnerable groups to improve impaired balance and thus prevent falls, subsequent injuries and loss of independence. The aim of the project is to characterize the mechanisms of sensory control in maintaining balance in various sensory conditions in elderly people with movement and cognitive disorders and to define indicators of postural stability that most sensitively reflect changes in balance control due to physical and sensory training. |
CARTRE - Investigation of factors involved in cardiorenal syndrom and treatment strategies
Skúmanie faktorov zapojených v kardiorenálnom syndróme a stratégie liečby
| Duration: | 1. 3. 2025 - 31. 12. 2028 |
| Evidence number: | VV-MVP-24-0278 |
| Program: | APVV |
| Project leader: | RNDr. Sýkora Matúš PhD. |
| Annotation: | The healthy physiological functioning of the body is ensured by the mutual interaction of individual organs, whereby pathological damage to one organ can cause acute or chronic dysfunction in another organ. The heart and kidneys interact through hemodynamic and non-hemodynamic pathways essential for cardiovascular homeostasis. The maladaptive relationship between the heart and kidneys has been defined as cardiorenal syndrome (CRS), contributing to organ dysfunction and failure. A key factor in this process is the activation of profibrotic pathways and subsequent fibrosis of the heart and kidneys. This life-threatening condition remains an unresolved issue in clinical practice. Therefore, new strategies are urgently needed for early diagnosis and targeted intervention in the fibrosis of the heart and kidneys. The aim of the project is to phenotype profibrotic and fibrotic changes in the heart and kidneys in a relevant model of CRS induced by aortocaval fistula (ACF). In addition to determining circulating markers of oxidative stress, inflammation, and profibrotic factors, it is essential to identify the activation of signaling pathways, the extent of fibrosis, and proarrhythmic factors, including profibrotic and proarrhythmic changes in connexin 43 (Cx43) in the heart and its unexplored role in the kidneys. Another aim of the project is to explore the antiinflammatory and antifibrotic effects of selectively targeted substances (SGLT2i and GLP-1RAs) and their potential in reversing profibrotic signaling pathways, including signaling mediated by connexin channels. The results obtained from this project will provide new information for more targeted therapy of the pathogenesis of heart and kidney fibrosis and will present a challenge for the implementation of translational and clinical studies. |
Investigating the involvement of connexin-43 in rat brown and white adipose tissue in mechanisms of cardiovascular risk and cardioprotection.
Skúmanie účasti konexínu-43 v hnedom a bielom tukovom tkanive potkana v mechanizmoch kardiovaskulárneho rizika a kardioprotekcie.
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | VEGA 2/0133/24 |
| Program: | VEGA |
| Project leader: | RNDr. Egan Beňová Tamara PhD. |
Therapeutic intervention with bioactive compounds from bee products in experimental arthritis: evaluation of both articular and extra-articular complications
Terapeutické ovplyvnenie experimentálnej artritídy bioaktívnymi látkami zo včelích produktov: hodnotenie kĺbových a mimo-kĺbových komplikácií
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | 2/0079/24 |
| Program: | VEGA |
| Project leader: | PharmDr. Bauerová Katarína PhD., DrSc. |
| Annotation: | Bee products are a frequently studied due to their pharmacological properties. However, the identification of substances responsible for their properties is absent. The aimof the project is to characterize the effect of selected peptides and polyphenolic extracts from bee products on the articular manifestations of rheumatoid arthritis, but also on extra-articular manifestations with the aim of optimizing the conventional treatment. Adjuvant arthritis in rats will be used in the project. Polyphenolic extracts of bee pollen and honey will be tested, as well as melittin from bee venom, 10-hydroxydecanoic acid from royal jelly and the bee peptide apisimin. In addition to biometric indicators, markers of inflammation and oxidative stress will be determined in plasma and in relevant tissues. Study of cardioprotective mechanisms and of mitochondrial energetics will be carried out. Finally, the effectiveness of the most effective substance in combination with methotrexate and upadacitinib will be verified. |
Therapeutic potential of natural antioxidants 7,8-dihydroxyflavone and Naringin in animal model of depression
Terapeutický potenciál prírodných antioxidantov 7,8-dihydroxyflavónu a Naringínu v animálnom modeli depresie
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | 2/0122/24 |
| Program: | VEGA |
| Project leader: | RNDr. Vranková Stanislava PhD. |
| Annotation: | Depression is the most common mental disorder in the world. Pathomechanisms involved in the development of depression are mainly associated with the BDNF/TrkB/CREB signaling pathway. Affecting the BDNF/TrkB/CREB signaling pathway is a critical therapeutic target for inducing adult hippocampal neurogenesis and antidepressant therapy. Compounds capable of inducing rapid structural and functional rearrangement of neuronal networks are particularly attractive. Several of these psychoplastogens are naturally occurring antioxidants, such as 7,8-dihydroxyflavone (7,8-DHF) and Naringin. The aim of our study is to investigate the effects of 7,8-DHF and Naringin, as well as their combinations, on the development of depressive-like symptoms in animal model of depression. Results of this project will contribute to elucidating the pathogenesis of depression and their treatment possibilities. |
ToxiGut - ToxiGut: Modeling and Prediction of Drug and Chemical Side Effects in an In Vitro 3D Reconstituted Human Small Intestine Model
ToxiGut: Modelovanie a predikcia vedľajších účinkov liekov a chemických látok na in vitro 3D rekonštituovanom modeli tenkého čreva
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | 2/0123/25 |
| Program: | VEGA |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena ERT |
| Annotation: | The ToxiGut project proposes the development and internal validation of an advanced experimental system for studying the side effects of chemicals and pharmaceuticals on a human 3D reconstructed model of the small intestine. The project focuses on comparing static and dynamic methods of cultivating 3D tissue in a microfluidic device (Gut-on-chip concept), achieving a high level of simulation of the physiological conditions of the small intestine. The project will compare the obtained data with experimental results from the CaCo-2 line of human colorectal carcinoma, which is used for screening in preclinical pharmacological studies. However, this model does not reflect the complexity of the human intestinal environment and, like established animal models, provides inaccurate outputs for clinical studies. The project aims to provide a more efficient testing system that will improve the predictive ability of preclinical tests and increase the safety of patients in clinical trials while reducing costs and time. |
HYDMIM - Effects of mesenchymal stem cells and HMGB1 inhibitor on cardiovascular system after experimentally induced myocardial infarction in hypertension and diabetes mellitus
Účinky mezenchymálnych kmeňových buniek a inhibítora HMGB1 na kardiovaskulárny systém po experimentálne vyvolanom infarkte myokardu v hypertenzii a diabettes mellitus
| Duration: | 1. 7. 2023 - 30. 6. 2027 |
| Evidence number: | APVV-22-0271 |
| Program: | APVV |
| Project leader: | RNDr. Cebová Martina PhD. |
| Annotation: | Myocardial infarction is a serious disease of the coronary arteries, when part of the heart muscle dies and cardiac remodeling occurs as a result of persistent ischemia. The lack of oxygen and nutrients during ischemia results in inflammation, oxidative damage, and tissue degeneration. For a comprehensive understanding of the onset and progression of myocardial protection mechanisms during ischemia, it is necessary to monitor protective signaling molecules that can block or reverse the pathological process. Despite significant progress in the treatment of diseases of the cardiovascular system, myocardial infarction still remains the main cause of death in the world, especially in elderly patients with associated diseases such as hypertension and diabetes mellitus. The aim of the proposed project will be to clarify the significance of the nitric oxide signaling pathway after myocardial infarction in conditions of selected comorbidities. We will define the initial molecular and morphological changes that are caused by either the application of stem cells or glycyrrhizin, an HMGB1 inhibitor, applied after myocardial infarction. We will also examine the effectiveness of stem cells and glycyrrhizin to suppress pro-inflammatory and pro-fibrotic pathways with focus on PI3K-Akt-eNOS signaling pathway and JNK / Bax and TLR4 / NF-κB signaling pathway. The new results may provide information for targeted therapy aimed at the application of stem cells after myocardial infarction. In addition, in patients who are not suitable candidates for the given treatment, the application of an HMGB1 inhibitor can be an alternative for the treatment of myocardial infarction. |
-
Účinky nových antidiabetík/antiobezitík semaglutidu a tirzepatidu na kardiovaskulárny systém u 6 a 12-mesaačných samcov a samíc obéznych ZDF potkanov s diabetom 2. typu
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | 2/0139/25 |
| Program: | VEGA |
| Project leader: | Mgr. Ferenczyová Kristína PhD. |
Edifu - The effect of dimethyl fumarate on nuclear factor erythroid 2-related factor 2 activation and redox balance in chronic stress-exposed female rats with mild hypertension and comorbid hypertriglyceridemia
Účinok dimetylfumarátu na aktiváciu jadrového faktora NRF2 a redoxnú rovnováhu u samíc potkanov vystavených chronickému stresu s miernou hypertenziou a komorbidnou hypertriglyceridémiou
| Duration: | 1. 9. 2024 - 31. 8. 2026 |
| Evidence number: | 09I03-03-V04-00477 |
| Program: | Plán obnovy EÚ |
| Project leader: | Mgr. Mičurová Andrea PhD. |
| Annotation: | The number of hypertensive adults worldwide has dramatically increased in last 30 years. Hypertension found together with other comorbidities presents a risk factor for development of several diseases. Nowadays, stress is considered to be significant factor involved not only in development, but also progression of cardiovascular, psychological and other diseases. Several studies associated long-lasting stress with disturbances in redox balance in various tissues, mainly with increased reactive oxygen species production or decreased activity of antioxidant enzymes. Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that regulates the cytoprotection against toxic and oxidative insults through the expression of genes involved in antioxidant defense. Interestingly, recent studies indicate that expression of NRF2 is decreased under chronic stress and leads to significant changes in redox homeostasis. Since hypertension and comorbid hypertriglyceridemia are often found together and many adults are exposed to chronic stressors, the aim of this project is to specify the chronic stress-induced behavioural changes, disturbances in redox balance, expression of NRF2 and its activation with dimethyl fumarate in various tissues of female experimental model of prehypertension with comorbid triglyceridemia. |
-
Úloha starnutia v kardioprotektívnych účinkoch vybraných endogénnych a exogénnych intervencií voči ischemicko-reperfúznemu poškodeniu srdca
| Duration: | 1. 1. 2025 - 31. 12. 2028 |
| Evidence number: | 2/0068/25 |
| Program: | VEGA |
| Project leader: | Mgr. Kindernay Lucia PhD. |
sulfidmenopau - The impact of menopause on the vasoregulatory role of the sulfide signaling pathway in cardiovascular complications of diabetes II type
Vplyv menopauzy na vazoregulačnú úlohu sulfidovej signálnej dráhy pri kardiovaskulárnych komplikáciách diabetu II.
| Duration: | 1. 9. 2025 - 31. 8. 2029 |
| Evidence number: | APVV-24-0150 |
| Program: | APVV |
| Project leader: | RNDr. Čačányiová Soňa PhD. |
| Annotation: | Hydrogen sulfide (H2S) is an important gaseous molecule involved in the regulation of vascular tone, including various pathological conditions such as hypertension, diabetes and obesity. Perivascular adipose tissue (PVAT), along with its pro-inflammatory activities and influence on vasoactive functions are also important in the development of cardiovascular complications. Interactions occur between these factors, but the exact mechanism remains unknown. It seems that the progression of metabolic disorders can significantly affect the balance between the pathological and compensatory effects of the sulfide signaling pathway. Inflammation and dysregulation of PVAT are particularly characteristic of advanced stages of diabetes, which could negatively impact the compensatory vasoactive effects of H2S observed in milder metabolic disorders. Confirming or disproving this assumption is one of the goals of the proposed project. Currently, increased attention is focused on aspects of personalized medicine that could contribute to more effective therapy by precisely targeting specific patient groups. The development of cardiovascular complications and diabetes is significantly higher in postmenopausal women, while in women under 40 years of age, the risk is lower than in men of the same age. The project aims to examine the impact of reproductive status in obese female rats with type II diabetes (ZDF) following surgical ovariectomy. The goal is to identify potential differences in the mechanisms underlying cardiovascular disorders, which might help in better specifying therapeutic targets for obese diabetic postmenopausal women with severe dyslipidemia. Selected plasma parameters will be compared with those of diabetic female patients of different reproductive ages. In the next phase, the project will investigate the potential beneficial effects of the natural isothiocyanate and slow-releasing H2S donor erucin, in reducing developed vascular complications in ovariectomized ZD |
The effect sex and reproductive stage of females on the vasoregulatory role of sulfide and nitroso signaling pathways in metabolic syndrome
Vplyv pohlavia a reprodukčného stavu samíc na vazoregulačnú úlohu sulfidovej a nitrózovej signánej dráhy v podmienkach metabolického syndrómu
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | 2/0153/24 |
| Program: | VEGA |
| Project leader: | Mgr. Berényiová Andrea PhD. |
| Annotation: | Our studies demonstrated a key vasoregulatory role of nitric oxide (NO) and hydrogen sulfide (H2S) signaling in various animal models of cardiovascular complications. In metabolic syndrome (MS) induced by changed diet, we reported that the interaction of these signaling pathways is disrupted, and H2S donor application can alleviate the pathological manifestations of MS. Moreover, in hypertriglyceridemic rats (HTG) we observed an endothelial dysfunction that was not only associated with reduced NO-synthase activity but also with endogenously produced H2S. Previous studies have focused on cardiovascular changes mainly in males, while studies on HTG females are missing. The project will examine the influence of gender and reproductive status of females HTG rats with the aim of revealing possible differences in vasoactive regulatory mechanisms. At the same time, it will investigate the possible beneficial effects of flavonoid administration on cardiovascular complication associated with postmenopausal MS. |
The role of sex hormones in the a1AMPK- mediated vascular protection during the development of the metabolic syndrome
Vplyv pohlavných hormónov pri indukcii vaskulárnej ochrany sprostredkovanej aktiváciou alfa-1 AMPK počas rozvoja metabolického syndrómu
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | 2/0123/24 |
| Program: | VEGA |
| Project leader: | Ing. Tarcalová Miroslava PhD. |
| Annotation: | Disruption of vascular homeostasis caused by reduced nitric oxide bioavailability due to oxidative stress and inflammation is the most severe complication of metabolic syndrome (MetS). Therefore, it is essential to identify the key factors that protect the endothelium and improve the primary and secondary prevention of cardiovascular diseases. Such a factor may be a1AMP-dependent protein kinase (a1AMPK), as it may be involved in improving metabolic control. The project focuses on risk factors affecting endothelial function during MetS and a1AMPK as a potential tool to modify these factors in the context of gender differences, as sex hormones can regulate a1AMPK. The project’s originality is based on a comprehensive assessment of changes in endothelial function during MetS with a clear focus on vascular endothelium and gender differences. The results of this study represent a potential tool to increase the quality of life and reduce the economic burden associated with treating this cardiometabolic disease. |
The influence of semantic representation and executive control on the structure and dynamics of idea generation
Vplyv sémantickej reprezentácie a exekutívnej kontroly na reguláciu štruktúry a dynamiky myslenia
| Duration: | 1. 7. 2024 - 30. 6. 2028 |
| Program: | APVV |
| Project leader: | Mgr. Marko Martin PhD. |
| Annotation: | Human thinking emerges from a complex interaction of several neurocognitive processes and mechanisms that are yet poorly understood. Following the recent advances in cognitive psychology and neuroscience, in the present project, we introduce an integrative framework where the unfolding “stream of thought” is conceptualized as a dynamic memory process operating upon structured conceptual representations constrained by situational demands (i.e., contexts or goals). To understand how semantic cognition aids adaptive ideation, we will first develop an original memory paradigm, allowing us to deconstruct the complexity of thinking into fundamental and measurable processes and functions. Using these measures in a series of behavioral and psychophysiological experiments implementing a systematic manipulation of cognitive interference and load, we will further investigate the core determinants and predictors of ideational fluency at various levels of analysis. Moreover, we will employ unifocal as well as bifocal non-invasive electrical brain stimulation and rigorous experimentation to evaluate the causal involvement of the prefrontal cortex and the cerebellum in semantic memory retrieval and control, hence shedding light on the mechanisms and circuits supporting both spontaneous and controlled (i.e., goal-oriented) idea generation. Together, the proposed framework and paradigms bear strong potential to bring novel insights into the architecture of human thinking and inspire future diagnostic procedures or non-pharmacological treatments for individuals with neuropsychiatric conditions that manifest in aberrant memory functioning, language, or thinking. |
Research of plants with therapeutic potential in surgery, dermatology, and dentistry: phytochemical analysis, biological effects, and study of mutual interactions of their constituents.
Výskum rastlín s terapeutickým potenciálom v chirurgii, dermatológii a stomatológii: fytochemická analýza, biologické účinky a štúdium vzájomných interakcií ich obsahových látok.
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | VEGA 1/0170/24 |
| Program: | VEGA |
| Project leader: | Ing. Račková Lucia PhD. |
DruCARI - Development of novel selective aldose reductase inhibitors (ARIs) with antioxidant properties and improved bioavailability as potential drugs in prevention of diabetes and cancer
Vývoj nových selektívnych inhibítorov aldóza reduktázy (ARI) s antioxidačnými vlastnosťami a vylepšenou biodostupnosťou ako potenciálnych liečiv v prevencii diabetu a rakoviny
| Duration: | 1. 9. 2025 - 31. 8. 2029 |
| Evidence number: | APVV-24-0388 |
| Program: | APVV |
| Project leader: | RNDr. Kováčiková Lucia PhD. |
| Annotation: | Multifactorial nature of diabetic complications represents a great challenge in the development of efficient therapy. The multitarget directed approach in prevention of diabetic complications is oriented on the rational design of chemical entities able to affect simultaneously multiple key mechanisms of glucose toxicity, namely non-enzymatic glycation, polyol pathway, oxidative stress and impaired calcium signaling, since targeting just one particular mechanism may have a limited effect. Aldose reductase inhibitors (ARIs) have been developed as therapeutics for the treatment of diabetic complications, inflammation and some types of cancer associated with chronic inflammation. No AR inhibitors have been approved in the USA and Europe. In Asia, epalrestat is used as the only one commercially available low selective inhibitor to treat diabetic neuropathy. In our previous study, we identified sulfur derivative cemtirestat (CMTI) and its oxygen analogue otirestat (OTI) as lead structures. Structure optimization by introducing various substituents into the N(2) position of OTI provided new possibilities for explanation of selectivity in related aldehyde reductase enzyme (ALR1). The aim of this project is development of novel selective ARIs with antioxidant properties and improved bioavailability as potential drugs for efficient therapy in diabetic complications and cancer. |
| Project web page: | https://portal.apvv.sk |
The role of in Wnt signaling in processes associated with effects of doxorubicin.
Wnt signalizácia a jej úloha v procesoch spojených s účinkami doxorubicínu.
| Duration: | 1. 1. 2024 - 31. 12. 2027 |
| Evidence number: | VEGA 2/0169/24 |
| Program: | VEGA |
| Project leader: | RNDr. Barančík Miroslav DrSc. |
Cardiac mitochondrial bioenergetics regulated by reduced oxygen consumption: In-depth proteomic analysis of cardioprotective signaling pathways.
Zníženou spotrebou kyslíka regulovaná bioenergetika srdcových mitochondrií: Hĺbková proteomická analýza signálnych kardioprotektívnych dráh.
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 2/0016/23 |
| Program: | VEGA |
| Project leader: | Ing. Ferko Miroslav PhD. |
| Annotation: | Reduced oxygen utilization significantly increases the myocardial energy requirements. The compensatory mechanisms against this serious metabolic disorder is associated with regulation of cardiac mitochondria. It is mitochondrial dysfunction that is currently the goal of a therapeutic cardioprotective strategy, effective against energy and dynamic imbalance. Part of the identification of preconditioning-induced adaptation processes will be the monitoring of the role of mitochondria on redox equilibrium, signaling of free oxygen radicals, changes in oxidative phosphorylation and energy pathways, mitochondrial dynamics and ion homeostasis. The definition of hypoxic damage, the effect of preconditioning and the identification of a potential cardioprotective signal carrier will be indicated by proteomic and metabolomic analyzes by LC-MS. The comprehensive analysis will provide detailed information on changes of proteins as potential markers as well as the characteristics of their signaling pathways. |
Projects total: 74